1992
DOI: 10.1159/000098934
|View full text |Cite
|
Sign up to set email alerts
|

Brachytherapy of Brain Tumors

Abstract: Temporary implants of high-activity 125iodine sources have been used in the treatment of brain tumors since December 1979 at the University of California, San Francisco. For previously untreated patients who underwent external beam radiation therapy followed by implant boost, median survival from the date of diagnosis was 88 weeks for 34 patients with glioblastoma multiforme (GM) and 157 weeks for 29 patients with nonglioblastoma gliomas (NGM). For recurrent tumors treated with brachytherapy only, m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2001
2001
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…Sometimes radiotherapy was combined with chemotherapy regimens [109,118,125,138] or hyperthermia [145], or was given after seed implantation [108]. …”
Section: Reviewmentioning
confidence: 99%
See 1 more Smart Citation
“…Sometimes radiotherapy was combined with chemotherapy regimens [109,118,125,138] or hyperthermia [145], or was given after seed implantation [108]. …”
Section: Reviewmentioning
confidence: 99%
“…Median survival after implantation varies from 4 to 18 months, and 12- and 18-months survival rates from 33 to 72% and from 25 to 33% [104,115,145,149-151,153,155-161]. …”
Section: Reviewmentioning
confidence: 99%
“…Although interstitial radiotherapy has been used to treat tumors for more than 100 years, it has been applied against intracranial tumor in China for only a few years. The form of radionuclide most frequently used for intracranial glioma is 125 I seeds [3,4] which posseses advantages of low average energy, quick energy attenuation beyond an effective distance, long half-life time, and an ease in safe guarding and preserving the radioactivity. Some studies have shown that 125 I can be tolerated by brain tissue, and can produce a satisfactory therapeutic efficacy [5,6] .…”
Section: Discussionmentioning
confidence: 99%
“…In inoperable patients that are clinically eligible for treatment, external beam radiotherapy (EBRT) [3], systemic chemotherapy (CHT) [4], or a combination of both [5,6,7] are the most common utilized modalities prolonging survival up to 14 months. While the role of interstitial (IRT) brachytherapy (BRT) in the treatment of high-grade gliomas has been studied in the adjuvant [8] and recurrence setting [9], there are very few data concerning its implementation in the primary treatment of inoperable GBM [10,11,12,13,14]. In the present single-institute analysis, we report our experience with computed tomography (CT)-guided high-dose rate (HDR) BRT in the primary treatment of inoperable GBM in the pre-temozolomide (TMZ) era.…”
Section: Purposementioning
confidence: 99%